248 related articles for article (PubMed ID: 2885637)
1. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh.
Lancet; 1987 Jul; 2(8552):171-5. PubMed ID: 2885637
[TBL] [Abstract][Full Text] [Related]
2. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Analysis at six years by Nolvadex Adjuvant Trial Organisation.
Lancet; 1985 Apr; 1(8433):836-40. PubMed ID: 2858709
[TBL] [Abstract][Full Text] [Related]
3. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors.
Fisher B; Costantino J; Redmond C; Poisson R; Bowman D; Couture J; Dimitrov NV; Wolmark N; Wickerham DL; Fisher ER
N Engl J Med; 1989 Feb; 320(8):479-84. PubMed ID: 2644532
[TBL] [Abstract][Full Text] [Related]
4. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study.
Bianco AR; De Placido S; Gallo C; Pagliarulo C; Marinelli A; Petrella G; D'Istria M; Delrio G
Lancet; 1988 Nov; 2(8620):1095-9. PubMed ID: 2903322
[TBL] [Abstract][Full Text] [Related]
6. The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group.
Stewart HJ
J Natl Cancer Inst Monogr; 1992; (11):117-20. PubMed ID: 1320920
[TBL] [Abstract][Full Text] [Related]
7. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
8. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer. Interim analysis at four years by Nolvadex Adjuvant Trial Organisation.
Lancet; 1983 Feb; 1(8319):257-61. PubMed ID: 6130291
[TBL] [Abstract][Full Text] [Related]
9. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials.
Fisher B; Jeong JH; Bryant J; Anderson S; Dignam J; Fisher ER; Wolmark N;
Lancet; 2004 Sep 4-10; 364(9437):858-68. PubMed ID: 15351193
[TBL] [Abstract][Full Text] [Related]
10. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 Sep; 352(9132):930-42. PubMed ID: 9752815
[TBL] [Abstract][Full Text] [Related]
11. The effect of adjuvant tamoxifen: the latest results from the Cancer Research Campaign Adjuvant Breast Trial. Cancer Research Campaign Breast Cancer Trials Group.
Eur J Cancer; 1992; 28A(4-5):904-7. PubMed ID: 1524921
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant tamoxifen treatment of elderly women with stage II breast cancer. A double-blind comparison with placebo.
Cummings FJ; Gray R; Davis TE; Tormey DC; Harris JE; Falkson G; Arseneau J
Ann Intern Med; 1985 Sep; 103(3):324-9. PubMed ID: 3896085
[TBL] [Abstract][Full Text] [Related]
13. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial.
Overgaard M; Jensen MB; Overgaard J; Hansen PS; Rose C; Andersson M; Kamby C; Kjaer M; Gadeberg CC; Rasmussen BB; Blichert-Toft M; Mouridsen HT
Lancet; 1999 May; 353(9165):1641-8. PubMed ID: 10335782
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant tamoxifen in postmenopausal breast cancer: preliminary results of a randomized trial.
Delozier T; Julien JP; Juret P; Veyret C; Couëtte JE; Graic Y; Ollivier JM; de Ranieri E
Breast Cancer Res Treat; 1986; 7(2):105-9. PubMed ID: 3521767
[TBL] [Abstract][Full Text] [Related]
15. Benefit and projected cost-effectiveness of anastrozole versus tamoxifen as initial adjuvant therapy for patients with early-stage estrogen receptor-positive breast cancer.
Hillner BE
Cancer; 2004 Sep; 101(6):1311-22. PubMed ID: 15368322
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant endocrine therapy for operable breast cancer.
Stewart HJ
Bull Cancer; 1991; 78(4):379-84. PubMed ID: 1859906
[TBL] [Abstract][Full Text] [Related]
17. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93.
; Colleoni M; Gelber S; Goldhirsch A; Aebi S; Castiglione-Gertsch M; Price KN; Coates AS; Gelber RD
J Clin Oncol; 2006 Mar; 24(9):1332-41. PubMed ID: 16505417
[TBL] [Abstract][Full Text] [Related]
18. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial.
Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B;
Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287
[TBL] [Abstract][Full Text] [Related]
19. Randomised controlled trial of conservation therapy for breast cancer: 6-year analysis of the Scottish trial. Scottish Cancer Trials Breast Group.
Forrest AP; Stewart HJ; Everington D; Prescott RJ; McArdle CS; Harnett AN; Smith DC; George WD
Lancet; 1996 Sep; 348(9029):708-13. PubMed ID: 8806289
[TBL] [Abstract][Full Text] [Related]
20. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
